{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:17:41Z","timestamp":1793521061889,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Despite the preclinical evidence on protective effects of colchicine against kidney fibrosis, whether colchicine could delay the progression of chronic kidney disease (CKD) in humans remains unknown. This study examined the association between long-term colchicine use and risk of adverse kidney outcome in patients with CKD who were treated for hyperuricaemia or chronic gout.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a multicentre, nested, case-control study in three Korean hospitals. Patients were aged \u226519\u2009years; had CKD G3\u2013G4; and used drugs including colchicine, allopurinol and febuxostat for hyperuricaemia or chronic gout during the period from April 2000 to October 2020. Patients with CKD progression, which was defined as \u226540% decrease from the baseline estimated glomerular filtration rate or the onset of kidney failure with replacement therapy, were matched to controls based on follow-up time, age and sex.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 3085 patients with CKD progression were matched to 11\u2009715 control patients. Multivariate conditional logistic regression analysis showed that patients with \u226590 cumulative daily colchicine doses were associated with a lower risk of CKD progression [adjusted odds ratio (AOR), 0.77; 95% CI: 0.61, 0.96] than non-users. In the sensitivity analysis with matched CKD stages, the AOR was 0.77 (95% CI: 0.62, 0.97). This association was more pronounced in patients without diabetes or hypertension, and in patients with CKD G3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Colchicine use is associated with a lower risk of adverse kidney outcomes in CKD patients with hyperuricaemia, or chronic gout.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac077","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T12:21:08Z","timestamp":1643804468000},"page":"4314-4323","source":"Crossref","is-referenced-by-count":12,"title":["Colchicine use and the risk of CKD progression: a multicentre nested case-control study"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6305-452X","authenticated-orcid":false,"given":"Hyung Woo","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University , Seoul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-0928","authenticated-orcid":false,"given":"Young Su","family":"Joo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University , Seoul"},{"name":"Division of Nephrology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Ryong","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University , Seoul"},{"name":"Division of Nephrology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Health Insurance Corporation Medical Center, Ilsan Hospital , Gyeonggi-do"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hyun","family":"Jhee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University , Seoul"},{"name":"Division of Nephrology, Department of Internal Medicine, Gangnam Severance Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Ho","family":"Roh","sequence":"additional","affiliation":[{"name":"Biostatistics Collaboration Unit, Department of Biomedical Systems Informatics, Yonsei University College of Medicine , Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2325-8982","authenticated-orcid":false,"given":"Jung Tak","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University , Seoul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Ik","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Health Insurance Corporation Medical Center, Ilsan Hospital , Gyeonggi-do"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hyun","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University , Seoul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Wook","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University , Seoul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-5635","authenticated-orcid":false,"given":"Seung Hyeok","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University , Seoul"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"2022110207585326800_keac077-B1","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"2022110207585326800_keac077-B2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","article-title":"Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study","volume":"164","author":"Niskanen","year":"2004","journal-title":"Arch Intern Med"},{"key":"2022110207585326800_keac077-B3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2215\/CJN.09420911","article-title":"Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality","volume":"7","author":"Liu","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022110207585326800_keac077-B4","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3899\/jrheum.121061","article-title":"Serum urate and incidence of kidney disease among veterans with gout","volume":"40","author":"Krishnan","year":"2013","journal-title":"J Rheumatol"},{"key":"2022110207585326800_keac077-B5","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1681\/ASN.2007101075","article-title":"Uric acid and incident kidney disease in the community","volume":"19","author":"Weiner","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2022110207585326800_keac077-B6","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2215\/CJN.03140315","article-title":"Serum uric acid and risk of CKD in type 2 diabetes","volume":"10","author":"De Cosmo","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022110207585326800_keac077-B7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.ajkd.2017.08.017","article-title":"Uric acid and the risks of kidney failure and death in individuals with CKD","volume":"71","author":"Srivastava","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2022110207585326800_keac077-B8","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"key":"2022110207585326800_keac077-B9","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"key":"2022110207585326800_keac077-B10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2022110207585326800_keac077-B11","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2022110207585326800_keac077-B12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/med.20097","article-title":"Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin","volume":"28","author":"Bhattacharyya","year":"2008","journal-title":"Med Res Rev"},{"key":"2022110207585326800_keac077-B13","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2022110207585326800_keac077-B14","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2022110207585326800_keac077-B15","doi-asserted-by":"crossref","first-page":"F200","DOI":"10.1152\/ajprenal.90649.2008","article-title":"Colchicine attenuates inflammatory cell infiltration and extracellular matrix accumulation in diabetic nephropathy","volume":"297","author":"Li","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022110207585326800_keac077-B16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mlc.2002.124397","article-title":"Colchicine decreases apoptotic cell death in chronic cyclosporine nephrotoxicity","volume":"139","author":"Li","year":"2002","journal-title":"J Lab Clin Med"},{"key":"2022110207585326800_keac077-B17","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.transproceed.2004.05.078","article-title":"Effect of colchicine on cyclosporine nephrotoxicity, reduction of TGF-beta overexpression, apoptosis, and oxidative damage: an experimental animal study","volume":"36","author":"Disel","year":"2004","journal-title":"Transplant Proc"},{"key":"2022110207585326800_keac077-B18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3904\/kjim.2016.131","article-title":"Effects of colchicine on renal fibrosis and apoptosis in obstructed kidneys","volume":"33","author":"Kim","year":"2018","journal-title":"Korean J Intern Med"},{"key":"2022110207585326800_keac077-B19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1681\/ASN.V13257","article-title":"Moderate protection of renal function and reduction of fibrosis by colchicine in a model of anti-GBM disease in the rabbit","volume":"1","author":"McClurkin","year":"1990","journal-title":"J Am Soc Nephrol"},{"key":"2022110207585326800_keac077-B20","doi-asserted-by":"crossref","first-page":"F1466","DOI":"10.1152\/ajprenal.00057.2013","article-title":"Colchicine attenuates renal injury in a model of hypertensive chronic kidney disease","volume":"305","author":"Guan","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022110207585326800_keac077-B21","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2022110207585326800_keac077-B22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022110207585326800_keac077-B23","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem"},{"key":"2022110207585326800_keac077-B24","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/ije\/dys147","article-title":"Case-control studies: basic concepts","volume":"41","author":"Vandenbroucke","year":"2012","journal-title":"Int J Epidemiol"},{"key":"2022110207585326800_keac077-B25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2022110207585326800_keac077-B26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1089\/rej.2016.1834","article-title":"Hyperuricemia, cardiovascular profile, and comorbidity in older men and women: the Pro.V.A. Study","volume":"20","author":"Musacchio","year":"2017","journal-title":"Rejuvenation Res"},{"key":"2022110207585326800_keac077-B27","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/4rrgyt","article-title":"Impact of disease duration and gender on the sensitivity and specificity of 2015 ACR\/EULAR classification criteria for gout. Cross-sectional results from an Italian multicentric study on the management of crystal-induced arthritis (ATTACk)","author":"Lorenzin","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2022110207585326800_keac077-B28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","article-title":"Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options","volume":"15","author":"Bardin","year":"2017","journal-title":"BMC Med"},{"key":"2022110207585326800_keac077-B29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","article-title":"Management of gout and hyperuricemia in CKD","volume":"70","author":"Vargas-Santos","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2022110207585326800_keac077-B30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/MJT.0b013e318250f83d","article-title":"Management of gouty arthritis in patients with chronic kidney disease","volume":"21","author":"Abdellatif","year":"2014","journal-title":"Am J Ther"},{"key":"2022110207585326800_keac077-B31","doi-asserted-by":"crossref","first-page":"e50046","DOI":"10.1371\/journal.pone.0050046","article-title":"Reduced glomerular function and prevalence of gout: NHANES 2009-10","volume":"7","author":"Krishnan","year":"2012","journal-title":"PLoS One"},{"key":"2022110207585326800_keac077-B32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2215\/CJN.06790616","article-title":"The 3-year incidence of gout in elderly patients with CKD","volume":"12","author":"Tan","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022110207585326800_keac077-B33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a Scientific Workshop Organized by the National Kidney Foundation","volume":"71","author":"Johnson","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2022110207585326800_keac077-B34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10157-012-0609-3","article-title":"Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy","volume":"16","author":"Omori","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"2022110207585326800_keac077-B35","doi-asserted-by":"crossref","first-page":"F993","DOI":"10.1152\/ajprenal.00637.2014","article-title":"Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy","volume":"308","author":"Kim","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022110207585326800_keac077-B36","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1111\/bph.13527","article-title":"Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes","volume":"173","author":"Komers","year":"2016","journal-title":"Br J Pharmacol"},{"key":"2022110207585326800_keac077-B37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ndt\/gfm783","article-title":"Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia","volume":"23","author":"Sanchez-Lozada","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2022110207585326800_keac077-B38","doi-asserted-by":"crossref","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","article-title":"Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism","volume":"282","author":"Mazzali","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022110207585326800_keac077-B39","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/hy1101.092839","article-title":"Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism","volume":"38","author":"Mazzali","year":"2001","journal-title":"Hypertension"},{"key":"2022110207585326800_keac077-B40","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2022110207585326800_keac077-B41","doi-asserted-by":"crossref","first-page":"e1002725","DOI":"10.1371\/journal.pmed.1002725","article-title":"No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization study","volume":"16","author":"Jordan","year":"2019","journal-title":"PLoS Med"},{"key":"2022110207585326800_keac077-B42","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/ki.2013.353","article-title":"Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function","volume":"85","author":"Hughes","year":"2014","journal-title":"Kidney Int"},{"key":"2022110207585326800_keac077-B43","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2022110207585326800_keac077-B44","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/ard.2008.092619","article-title":"Opportunities for improving medication use and monitoring in gout","volume":"68","author":"Singh","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022110207585326800_keac077-B45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40261-014-0238-6","article-title":"Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease","volume":"34","author":"Wason","year":"2014","journal-title":"Clin Drug Investig"},{"key":"2022110207585326800_keac077-B46","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022110207585326800_keac077-B47","volume-title":"Epidemiology: beyond the basics","author":"Szklo","year":"2014"},{"key":"2022110207585326800_keac077-B48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13075-021-02416-y","article-title":"Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review","volume":"23","author":"Pisaniello","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2022110207585326800_keac077-B49","author":"Food and Drug Adminitration"},{"key":"2022110207585326800_keac077-B50","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1097\/MJT.0b013e31825a364a","article-title":"Colchicine toxicity in end-stage renal disease patients: a case-control study","volume":"21","author":"Solak","year":"2014","journal-title":"Am J Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac077\/43638223\/keac077.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/11\/4314\/46747658\/keac077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/11\/4314\/46747658\/keac077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T08:00:17Z","timestamp":1667376017000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/11\/4314\/6525250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,2,9]]},"published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac077","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,2,9]]}}}